Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
This website contains data provided by Euronext. This data is provided "as is" for information purposes only without any guarantees. Although all reasonable precautions have been taken to ensure the accuracy of the data, Euronext does not guarantee accuracy or completeness. Oncodesign cannot be held responsible for the use of these data. This information cannot be considered as creating rights or commitments from Oncodesign or any representative company.
A true entrepreneurial project and a rare occurrence in biotechnology, Oncodesign’s capital is mainly held by its managers, including Dr. Philippe Genne, CEO and Founder of the company. The interests of management and shareholders remain perfectly aligned.